MINNEAPOLIS, Oct 23, 2008 (UPI via COMTEX) -- A U.S. study has determined why
episodic treatment of the human immunodeficiency virus and AIDS with
anti-retroviral drugs increases the overall risk of death.
James Neaton of the University of Minnesota and colleagues said it was known
intermittent HIV/AIDS treatment was tied to inflammation and blood-clotting when
compared with continuous antiretroviral treatment, or ART. But the reasons for
that were unknown.
Neaton and colleagues have discovered higher levels of certain markers of
inflammation and blood-clotting are strongly associated with intermittent ART
and with a higher risk of death from non-AIDS diseases.
The scientists said they determined people who began the study with relatively
higher levels of the biomarkers interleukin-6 and D-dimer were at greater risk
of death than other study participants.
The new research appears in the journal PLoS Medicine.
URL: www.upi.com
Copyright 2008 by United Press International